Download PDF
Aktuelle Kardiologie 2023; 12(01): 34-38
DOI: 10.1055/a-1953-5670
Kurzübersicht

Therapie der chronisch thromboembolischen pulmonalen Hypertonie

Treatment of Chronic Thromboembolic Pulmonary Hypertension
Christoph B. Wiedenroth
1   Thoracic Surgery, Kerckhoff Klinik GmbH, Bad Nauheim, Deutschland
,
Eckhard Mayer
1   Thoracic Surgery, Kerckhoff Klinik GmbH, Bad Nauheim, Deutschland
,
Stefan Guth
1   Thoracic Surgery, Kerckhoff Klinik GmbH, Bad Nauheim, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die chronisch thromboembolische pulmonale Hypertonie (CTEPH) ist eine wichtige und oft gut behandelbare Form der pulmonalen Hypertonie. Es stehen aktuell 3 Therapiemodalitäten zur Verfügung: die pulmonale Endarteriektomie, die pulmonale Ballonangioplastie und die gezielte medikamentöse Behandlung. Das therapeutische Konzept hängt maßgeblich von der Lokalisation der zugrunde liegenden pulmonalarteriellen fibrösen Obstruktionen ab. Die pulmonale Endarteriektomie ist der Goldstandard in der Behandlung der CTEPH. Für inoperable Patienten stehen mittlerweile 2 zugelassene Substanzen (Riociguat und Treprostinil) zur Verfügung. Daneben wird bei Vorhandensein entsprechender Zielgebiete die interventionelle Therapie empfohlen. Evaluation und Behandlung von CTEPH-Patienten sollte in entsprechend erfahrenen Zentren erfolgen.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is an important form of pulmonary hypertension. Nowadays, three treatment modalities are available: pulmonary endarterectomy, pulmonary balloon angioplasty, and targeted medical treatment. The therapeutic concept depends mainly on the exact localization of the underlying pulmonary arterial obstructions. Pulmonary endarterectomy is the gold standard in the treatment of CTEPH. For inoperable patients, two approved drugs (riociguat and treprostinil) are available. In addition, interventional therapy is recommended if there are appropriate target lesions. Evaluation and treatment of CTEPH patients in experienced centers is mandatory.

Was ist wichtig?

In den aktuellen europäischen PH-Leitlinien werden für operable Patienten die pulmonale Endarteriektomie (I B), für inoperable Patienten und für Patienten mit residueller/rezidivierender pulmonaler Hypertonie (PH) nach pulmonaler Endarteriektomie (PEA) die medikamentöse PH-Therapie (I B) sowie die pulmonale Ballonangioplastie bei Vorhandensein entsprechender Zielgebiete (I B) empfohlen.

Schlüsselwörter

chronisch thromboembolische pulmonale Hypertonie - pulmonale Endarteriektomie - pulmonale Ballonangioplastie

Keywords

chronic thromboembolic pulmonary hypertension - pulmonary endarterectomy - balloon pulmonary angioplasty


Publication History

Article published online:
09 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022;
    CrossrefPubMedSearch in Google Scholar
  • 2 Guerin L, Couturaud F, Parent F. et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014; 112: 598-605
    Search in Google Scholar
  • 3 Klok FA, Dzikowska-Diduch O, Kostrubiec M. et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 2016; 14: 121-128
    CrossrefPubMedSearch in Google Scholar
  • 4 Narechania S, Renapurkar R, Heresi GA. Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. Pulm Circ 2020; 10: 2045894019882620
    CrossrefPubMedSearch in Google Scholar
  • 5 Lasch F, Karch A, Koch A. et al. Comparison of MRI and VQ-SPECT as a screening test for patients with suspected CTEPH: CHANGE-MRI study design and rationale. Front Cardiovasc Med 2020; 7: 51
    CrossrefPubMedSearch in Google Scholar
  • 6 Humbert MS, Simonneau G, Pittrow D. et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2022; 41: 716-721
    CrossrefPubMedSearch in Google Scholar
  • 7 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-1371
    CrossrefPubMedSearch in Google Scholar
  • 8 Nagel C, Prange F, Guth S. et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012; 7: e41603
    CrossrefPubMedSearch in Google Scholar
  • 9 Nagel C, Nasereddin M, Benjamin N. et al. Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension as early follow-up treatment after pulmonary endarterectomy: a prospective cohort study. Respiration 2020; 99: 577-588
    CrossrefPubMedSearch in Google Scholar
  • 10 Kim NH, Delcroix M, Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915
    CrossrefPubMedSearch in Google Scholar
  • 11 Lankeit M, Krieg V, Hobohm L. et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2017;
    CrossrefPubMedSearch in Google Scholar
  • 12 Delcroix M, Lang I, Pepke-Zaba J. et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133: 859-871
    CrossrefPubMedSearch in Google Scholar
  • 13 Quadery SR, Swift AJ, Billings CG. et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52: 1800589
    CrossrefPubMedSearch in Google Scholar
  • 14 Ghofrani HA, D’Armini AM, Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329
    CrossrefPubMedSearch in Google Scholar
  • 15 Sadushi-Kolici R, Jansa P, Kopec G. et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 2019; 7: 239-248
    CrossrefPubMedSearch in Google Scholar
  • 16 Guth S, D’Armini AM, Delcroix M. et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res 2021; 7: 00850-2020
    CrossrefPubMedSearch in Google Scholar
  • 17 Brenot P, Jais X, Taniguchi Y. et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1802095
    CrossrefPubMedSearch in Google Scholar
  • 18 Kataoka M, Inami T, Hayashida K. et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 756-762
    CrossrefPubMedSearch in Google Scholar
  • 19 Mahmud E, Behnamfar O, Ang L. et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin 2018; 7: 103-117
    CrossrefPubMedSearch in Google Scholar
  • 20 Mizoguchi H, Ogawa A, Munemasa M. et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5: 748-755
    CrossrefPubMedSearch in Google Scholar
  • 21 Olsson KM, Wiedenroth CB, Kamp JC. et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017; 49: 1602409
    CrossrefPubMedSearch in Google Scholar
  • 22 Inami T, Kataoka M, Yanagisawa R. et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Circulation 2016; 134: 2030-2032
    CrossrefPubMedSearch in Google Scholar
  • 23 Jaïs X, Brenot P, Bouvaist H. et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med 2022; 10: 961-971
    CrossrefPubMedSearch in Google Scholar
  • 24 Cannon JE, Su L, Kiely DG. et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results From the UK National Cohort. Circulation 2016; 133: 1761-1771
    CrossrefPubMedSearch in Google Scholar
  • 25 Wiedenroth CB, Liebetrau C, Breithecker A. et al. Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2016; 35: 591-596
    CrossrefPubMedSearch in Google Scholar
  • 26 Mayer E, Jenkins D, Lindner J. et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141: 702-710
    CrossrefPubMedSearch in Google Scholar